Acadia Pharmaceuticals Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; balance-sheet amounts are as of March 31, 2024. Financial statements are unaudited. Acadia is a biopharmaceutical company commercializing NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome, while developing additional CNS and rare-disease candidates.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net product revenue | $205.8 million | $118.5 million |
| Operating income (loss) | $15.2 million | $(53.6) million |
| Net income (loss) | $16.6 million | $(43.0) million |
| Diluted earnings (loss) per share | $0.10 | $(0.27) |
| Operating cash flow | $29.1 million provided | $17.9 million used |
- Revenue increased 74% year over year. DAYBUE contributed $75.9 million; NUPLAZID revenue was $129.9 million, up $11.4 million (about 10%).
- Cost of product sales was $23.0 million, approximately 11% of revenue, versus $1.7 million, or 1%, a year earlier. The reported DAYBUE cost ratio is affected by pre-launch inventory whose manufacturing costs were previously expensed.
- Research and development expense declined to $59.7 million from $69.1 million, mainly because prior-year trofinetide commercial-supply costs were expensed before approval. Selling, general and administrative expense rose to $108.0 million from $101.2 million, reflecting annualized DAYBUE costs and investments supporting potential international commercialization.
- Cash, cash equivalents and available-for-sale investments totaled $470.5 million at quarter-end, up from $438.9 million at December 31, 2023. Cash, cash equivalents and restricted cash were $210.5 million.
- Total assets were $855.1 million; current assets were $675.3 million and current liabilities $330.6 million. The balance sheet reports no borrowings; operating lease liabilities totaled $59.6 million.
- Investing activities used $14.0 million, mainly reflecting purchases of investment securities net of sales and maturities. Financing activities provided $1.0 million.
Material developments, outlook and risks
- Management expects current cash, cash equivalents and investments to fund planned operations through and beyond the next 12 months, while noting that additional financing may be needed in the future. No specific full-year revenue or earnings guidance is provided in the supplied filing text.
- Acadia recorded a $50.0 million DAYBUE-related milestone as an intangible asset and accrued contingent payment. The payment is associated with the first calendar year North American trofinetide sales exceed $250 million and may be payable in the next 12 months. DAYBUE royalties to Neuren are 10% of North American net sales, rising to 12% on sales above the stated threshold.
- Management estimates that, after DAYBUE’s zero-cost inventory is depleted, cost of product sales will be in the mid-single-digit to high-single-digit percentage range of total net sales. It expects zero-cost inventory to be exhausted in 2025.
- Acadia reported that the Phase 3 ADVANCE-2 trial of pimavanserin for negative symptoms of schizophrenia did not meet its primary endpoint; the company does not intend to initiate further pimavanserin trials. Development focus includes Phase 3 ACP-101 for Prader-Willi syndrome and Phase 2 ACP-204 for Alzheimer’s disease psychosis.
- International DAYBUE efforts include an anticipated European filing in Q1 2025, a scheduled second-quarter 2024 discussion with Japan’s PMDA, and a Canadian submission accepted for priority review, with a possible decision around year-end 2024. These are company expectations, not assured outcomes.
- Two of five DAYBUE post-marketing studies were completed; the company was awaiting FDA acknowledgement and acceptance. Remaining studies, commercialization and pipeline advancement may add substantial expense.
- Material legal matters include ongoing NUPLAZID generic-patent litigation, including MSN’s appeal of a patent judgment and a separate trial scheduled for December 2024. Securities class-action and related derivative/opt-out matters are also pending. The company says litigation outcomes and potential losses cannot be predicted or estimated and has not accrued amounts beyond legal fees incurred.
- Key risks include dependence on NUPLAZID and DAYBUE adoption and reimbursement, regulatory and post-marketing requirements, clinical-development uncertainty, manufacturing and supply-chain dependence, patent challenges, litigation, and macroeconomic or geopolitical disruption. Management concluded disclosure controls were effective as of March 31, 2024.
Important facts for investors to verify
- Whether DAYBUE revenue growth and patient uptake continue, and how sales allowances, rebates and payer access affect net sales.
- Progress toward the $250 million North American DAYBUE sales milestone, the timing of the $50 million payment, and the impact of royalties and milestone amortization on margins and cash.
- Whether management’s cash-runway assessment remains valid as commercial, post-marketing, pipeline and potential international launch spending evolves.
- Updates on DAYBUE post-marketing requirements and Canadian, European and Japanese regulatory plans.
- Developments in NUPLAZID patent appeals and trials, and the securities and derivative litigation, including any changes to exposure or accrued amounts.
- Execution and results of ACP-101 and ACP-204 studies following the decision to discontinue further pimavanserin trials in schizophrenia.